Pancreatic adenocarcinoma:Beyond first line,where are we?

查看全文 作　　者：Sara [1]Cherri;Silvia [1]Noventa;Alberto [1]Zaniboni

机构地区：[1]Department of Oncology,Fondazione Poliambulanza,Brescia 25124,Italy

出　　处：《World Journal of Gastroenterology》索引2021年第27卷第17期,共17页

摘　　要：Pancreatic cancer is considered one of the most aggressive cancers,with an increasing incidence in recent years.To date,chemotherapy is still the standard of care for advanced metastatic disease,unfortunately providing only a slight advantage in terms of survival.The molecular and cellular characteristics of pancreatic cancer cells,as well as the cells that characterize the pancreatic tumour microenvironment,are the basis of the mechanisms of resistance to treatment.After progression during first-line treatment,few patients are eligible for secondline treatment due to the loss of performance status.To date,a clear survival advantage has not yet been demonstrated for second-line chemotherapy.Precision medicine could be the key to increasing responses to cancer treatment and finally impacting survival in this difficult-to-treat disease.In this review,we analyze current recommendations in the second-line setting and potential future prospects. 关键词：Pancreatic adenocarcinoma SECOND-LINE CHEMOTHERAPY Targeted therapy IMMUNOTHERAPY

相关文献

参考文献（94）
引证文献（1）
耦合文献（0）

参考文献(94)

引证文献(1)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Pancreatic adenocarcinoma:Beyond first line,where are we?

参考文献(94)

引证文献(1)

用户提示